Medical Oncologist
CION Cancer Clinics
RUNX1 and cancer: which cancers, and how much risk | CION Cancer Clinics
An inherited RUNX1 fault mainly raises the risk of blood cancers that start in the bone marrow, especially myelodysplastic syndrome and acute myeloid leukaemia. The risk is well above average, yet many carriers never develop either. This page explains which cancers are linked, what pushes one person's risk up or down, and why no web page can give you a personal figure. At CION Cancer Clinics, our oncologists explain what a gene result means for you and your family, and plan the checks that follow.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Which cancers does an inherited RUNX1 fault raise the risk of?
- What are the blood cancers linked to RUNX1?
- What pushes the risk up or down for one person?
- The risk words you will meet, in plain language
- What a RUNX1 risk means, and what it does not
- What this page cannot tell you
- Four things families tell us, and what is actually true
- Common questions about RUNX1 and cancer risk
The short answer
Which cancers does an inherited RUNX1 fault raise the risk of?
An inherited RUNX1 fault mainly raises the risk of blood cancers that start in the bone marrow. The two most common are myelodysplastic syndrome and acute myeloid leukaemia. The risk is well above that of the general population, but many carriers never develop either one.
Why the marrow, and not other organs
RUNX1 is a switch that tells young blood cells how to grow up. When one copy is faulty, the marrow still works, but it is more fragile. Over the years, marrow cells can pick up extra faults, and a group of damaged cells can slowly take over. That is how most RUNX1-linked cancers begin.
What the evidence does and does not show
The link with marrow cancers is clear and consistent across families. A link with breast, bowel or other solid cancers has not been shown. Most published families come from outside India, and the studies are small, so figures you read online vary a great deal.
What the platelets have to do with it
The same fault that raises the cancer risk also causes low or poorly working platelets, often from birth. That bleeding tendency is not a cancer and does not mean one is coming. It is simply the first sign that the gene is not working normally.
A raised risk is not a diagnosis. It is a reason to be watched by a haematologist, a doctor who treats blood disorders.The cancers involved
What are the blood cancers linked to RUNX1?
They are not all equally likely. The first two account for most of the raised risk.
Myelodysplastic syndrome
Often called MDS. The marrow makes blood cells that are faulty and too few. It can stay steady for a long time, or it can move on to leukaemia. It is often found first on a routine blood count.
Acute myeloid leukaemia
Often called AML. Immature marrow cells grow fast and crowd out healthy ones. It can arise on its own or after MDS.
Signs that need a prompt check
- New tiredness or breathlessness
- Fevers or infections that keep returning
- Bruising or bleeding worse than your usual
T-cell leukaemia
A leukaemia of T cells, a type of white cell, has been reported in some RUNX1 families. It is much less common than MDS or AML, but it is one reason any new symptom deserves a blood test.
Changes that are not yet cancer
Many carriers show small groups of marrow cells with extra faults, found on sensitive gene tests. This is watched closely. On its own it is not leukaemia, and it can stay stable for years.
Not sure whether this applies to you?
Ask an oncologistYour own picture
What pushes the risk up or down for one person?
The exact variant
Some RUNX1 faults switch off one copy of the gene. Others also interfere with the working copy. Studies suggest the second kind may carry a higher risk, though the evidence is still limited.
What happened to relatives
A family where several people developed leukaemia gives a clearer signal than one where nobody has. Even so, relatives with the same fault can have very different outcomes.
Extra faults in marrow cells
A sensitive gene panel on blood or marrow can show whether new faults are building up. Certain extra faults are a reason to watch more closely.
Changes in the blood count
A carrier's counts are compared against their own usual numbers. A steady low platelet count is expected. A new drop, or a change in other cells, is not.
Age
Blood cancer can appear in childhood or late in life, but the chance builds up over the years as marrow cells gather more damage.
On your report
The risk words you will meet, in plain language
- Myeloid
- Relating to the marrow cells that make red cells, platelets and some white cells. Most RUNX1-linked cancers are myeloid.
- Lifetime risk
- The chance of developing a cancer at some point in life. It is an average across many people, not a forecast for you.
- Penetrance
- How often a fault actually leads to disease across everyone who carries it. For RUNX1 it is raised but incomplete.
- Clonal haematopoiesis
- A group of blood cells that all descend from one cell with an extra fault. It is a warning sign to watch, not a cancer.
- Second hit
- A new fault that appears in a marrow cell during life, on top of the inherited one.
- Germline
- Present in every cell from birth, and so it can be passed to children. The opposite is somatic, found only in the cancer cells.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Side by side
What a RUNX1 risk means, and what it does not
It does mean
It does not mean
A higher chance of a marrow cancer
That leukaemia is certain
Regular blood counts with a haematologist
Treatment while you are well
Relatives can be tested for your variant
Extra screening for breast or bowel cancer
Care with painkillers and procedures
A change to your daily life or work
Being straight with you
What this page cannot tell you
It cannot give you a personal risk figure. Published figures come from a small number of families and vary between studies. A number read online may not apply to your variant or your family. Studies so far are small, and few include Indian families.
It cannot read your report
What your specific variant means is a question for the counsellor who ordered the test. Your haematologist will also weigh your blood counts, your marrow results and your family history before talking about your own risk.
Who this does not apply to
This page is about an inherited RUNX1 fault. If RUNX1 was found only in leukaemia cells, it may not be inherited at all, and the question is about treatment. That is covered under targeted therapy. Relatives who test negative for the family variant have the same risk as anyone else.
If RUNX1 appeared on a leukaemia report, ask whether a test on skin or hair is needed to confirm it is inherited.Commonly believed
Four things families tell us, and what is actually true
"RUNX1 means I will get leukaemia."
It raises the risk a great deal, but many carriers live their whole lives without a blood cancer. Regular checks aim to catch changes early if they do happen.
"My platelets have been low for years, so cancer is coming."
A steady low platelet count is part of the inherited condition itself. What matters is a change from your usual pattern, not the low number you have always had.
"Nobody in our family had leukaemia, so my risk is low."
Small families, early deaths and missed diagnoses can hide the pattern. The risk comes from the fault, so a quiet family history does not lower it on its own.
"It must raise the risk of every cancer."
The raised risk is in the blood and marrow. There is no clear evidence that a RUNX1 fault raises the risk of breast, bowel or other solid cancers.
Questions we are asked
Common questions about RUNX1 and cancer risk
At what age does RUNX1-linked leukaemia usually appear?
It can appear at almost any age, from childhood to old age. Many cases in RUNX1 families appear earlier than leukaemia usually does in the general population. That is one reason blood counts are checked from the time the fault is found.
Is my child's risk the same as mine?
A child who inherits the same fault carries a similar raised risk, though the outcome can differ even within one family. Each child of a carrier has a one in two chance of inheriting it. A child who tests negative has no raised risk from RUNX1.
Can anything lower the risk?
No medicine is proven to lower it. Not smoking, avoiding unnecessary radiation and chemical solvents, and keeping up with checks are sensible. The main benefit comes from finding a change early, while more treatment options are open.
Should a well carrier have a transplant to remove the risk?
Not usually. A stem cell transplant carries serious risks of its own and is not offered to well carriers with a healthy marrow. It is considered if worrying marrow changes or a blood cancer appear, and the donor must not carry the family fault.
Which symptoms should make me see a doctor early?
New tiredness, breathlessness, fevers, repeated infections, or bruising and bleeding that is worse than usual for you. None of these means cancer on its own. Each is a reason to have a blood count checked sooner rather than waiting for your next visit.
Does the type of variant change my risk?
It may. Some studies suggest faults that also block the working copy of the gene carry a higher risk. The evidence is still limited, so your haematologist will look at the variant alongside your blood tests and family history.
Do I need scans for other cancers?
Not because of RUNX1. The raised risk is in the blood and marrow, and blood tests are how it is watched. Routine screening for your age, such as for breast or cervical cancer, still applies as it would for anyone else.
Can the risk be explained to my family in Telugu?
Yes. A counsellor can go through the result and what it means for each relative in Telugu, and family members are welcome to join. Bring the report and any old blood counts, including those of relatives if you have them.
Your Specialists
Meet CION's oncologists. Bring your family history or genetic report to them.
Our medical oncologists see people with a strong family history of cancer, arrange genetic counselling and testing where it fits, and plan the checks that follow.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Hematologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- GeneReviews (NCBI) — RUNX1 Familial Platelet Disorder with Associated Myeloid Malignancies
- National Cancer Institute (PDQ) — RUNX1-Familial Platelet Disorder (PDQ): Health Professional Version
- MedlinePlus Genetics — RUNX1 gene
- Cancer Research UK — Acute myeloid leukaemia (AML)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
The RUNX1 gene: what it doesHow one faulty switch affects platelets and marrowSurveillance for RUNX1 carriersThe blood checks that watch for early changeFamilial platelet disorder with leukaemia riskThe condition behind the bleeding and the riskRUNX1 positive: what happens nextThe first steps after a positive result
Talk to us
Worried about what a RUNX1 result means for you?
Send us the report and any old blood counts. We will arrange a counsellor and a haematologist to explain your own risk and set up the right checks. One helpline serves every CION centre.